PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

Por Massacesi, Cristian, Di Tomaso, Emmanuelle, Urban, Patrick, Germa, Caroline, Quadt, Cornelia, Trandafir, Lucia, Aimone, Paola, Fretault, Nathalie, Dharan, Bharani, Tavorath, Ranjana, Hirawat, Samit
Publicado no Onco Targets Ther (2016)

A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours

Por FAZIO, NICOLA, BUZZONI, ROBERTO, BAUDIN, ERIC, ANTONUZZO, LORENZO, HUBNER, RICHARD A., LAHNER, HARALD, DE HERDER, WOUTER W., RADERER, MARKUS, TEULÉ, ALEXANDRE, CAPDEVILA, JAUME, LIBUTTI, STEVEN K., KULKE, MATTHEW H., SHAH, MANISHA, DEY, DEBARSHI, TURRI, SABINE, AIMONE, PAOLA, MASSACESI, CRISTIAN, VERSLYPE, CHRIS
Publicado no Anticancer Res (2016)

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

Por Vansteenkiste, Johan F., Canon, Jean-Luc, De Braud, Filippo, Grossi, Francesco, De Pas, Tommaso, Gray, Jhanelle E., Su, Wu-Chou, Felip, Enriqueta, Yoshioka, Hiroshige, Gridelli, Cesare, Dy, Grace K., Thongprasert, Sumitra, Reck, Martin, Aimone, Paola, Vidam, Gena Atalla, Roussou, Pantelia, Wang, Ying A., Tomaso, Emmanuelle Di, Soria, Jean-Charles
Publicado no J Thorac Oncol (2015)